Table 3.
Neutralizing antibody titers to each DENV serotype before and 28 days after the booster dose for each participant included in the booster ATP cohort for immunogenicity
| Group | Subject | DENV-1 | DENV-2 | DENV-3 | DENV-4 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | ||
| 1 μg + AS01E | A | 1,370 | 4,781 | 172 | 3,659 | 387 | 4,494 | 186 | 6,477 |
| B | 24 | 4,062 | 18 | 5,359 | 27 | 6,830 | < 10 | 28,440 | |
| C | 19 | 1,690 | 37 | 3,864 | 67 | 2,172 | < 10 | 3,557 | |
| D | 20 | 2,353 | < 10 | 3,894 | < 10 | 3,796 | < 10 | 23,770 | |
| E | 444 | 6,235 | 157 | 4,234 | 291 | 19,790 | 567 | 16,970 | |
| F | 32 | 27,350 | < 10 | 3,924 | 42 | 14,340 | < 10 | 34,410 | |
| 4 μg + alum | G | 30 | 7,570 | 64 | 3,989 | 45 | 3,747 | 12 | 20,390 |
| H | < 10 | 710 | < 10 | 153 | < 10 | 246 | < 10 | 528 | |
| I | 14 | 20,130 | 11 | 36,130 | 19 | 25,040 | < 10 | 40,080 | |
4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; ATP = according-to-protocol; Pre = blood sampling prebooster; Post = blood sampling 28 days after booster; participants with a titer below the assay cutoff are indicated with a value as < 10.